Holen Sie sich die Stockscreener-App
278.76
1.71%
-4.85
Handel nachbörslich:
278.76
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Amgen Sells Off: Keep Calm And Buy The Dip (NASDAQ:AMGN) - Seeking Alpha
Napa Wealth Management Acquires New Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Is Amgen Inc. (AMGN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Aljian Capital Management LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Short Interest Update - MarketBeat
Thrivent Financial for Lutherans Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Swiss National Bank Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Atlanta Consulting Group Advisors LLC Makes New $796,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Natixis Advisors LLC Has $94.32 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sawgrass Asset Management LLC Sells 11,850 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
GSA Capital Partners LLP Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Kinsale Capital Group Inc. Raises Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Mizuho Securities USA LLC Has $25.16 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kentucky Retirement Systems Has $12.06 Million Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious - MSN
Northcape Wealth Management LLC Increases Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
The three-year decline in earnings for Amgen NASDAQ:AMGN) isn't encouraging, but shareholders are still up 50% over that period - Yahoo Finance
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Amgen Inc (AMGN) Stock Price, Trades & News - GuruFocus.com
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Amazon.com Inc., Amgen share losses lead Dow's 275-point drop - MSN
Dow falls nearly 400 points on losses for shares of Amgen, Amazon.com Inc. - MSN
Amgen, Amazon.com Inc. share losses lead Dow's 288-point drop - MSN
A Journey of Courage: Empowering Others with Gastric Cancer - Marketscreener.com
Merck, Amgen share losses lead Dow's 168-point drop - MarketWatch
Amgen (NASDAQ:AMGN) Coverage Initiated by Analysts at Wolfe Research - MarketBeat
Amgen (NASDAQ:AMGN) Stock Rating Upgraded by Citigroup - MarketBeat
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 - PR Newswire
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate - Yahoo Finance
ING Groep NV Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
2 Dividend Stocks to Buy Hand Over Fist in November - The Motley Fool
Curi RMB Capital LLC Sells 1,681 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zions Bancorporation N.A. Has $5.27 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
KBC Group NV Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen speaks out about bone density concerns with obesity drug - Clinical Trials Arena
Is Wall Street Bullish or Bearish on Amgen Stock? - Nasdaq
Amgen (NASDAQ:AMGN) Coverage Initiated at Citigroup - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Bell Bank - MarketBeat
Is Wall Street Bullish Or Bearish On Amgen Stock? - Barchart
Citi sets Amgen neutral with $335 target on MariTide focus - Investing.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen's SWOT analysis: biotech giant's stock faces obesity market opportunity - Investing.com
MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM - PR Newswire
Amgen dismisses bone density concerns related to its weight-loss drug - Reuters
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density - Benzinga
Understanding Cardiovascular Risk: The Role of LDL-C, Comorbidities and Early Intervention - Amgen
BRIEF—Amgen dismisses obesity drug safety concern; investors unsure - The Pharma Letter
Amgen To Present At 2024 UBS GLOBAL HEALTHCARE CONFERENCE; Webcast At 1:15 PM ET - Nasdaq
Amgen plays down safety concern with obesity candidate - pharmaphorum
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Arjuna Capital - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Saturna Capital Corp - MarketBeat
Morning Brew: Amgen's Rebound, Flutter's Buyback, and Cybersecurity Surge - GuruFocus.com
Amgen Gain as Data Unearthed - Baystreet.ca
Amgen (AMGN) Clarifies: No Link Between Weight Loss Drug and Bon - GuruFocus.com
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Empower Advisory Group LLC - MarketBeat
Amgen Suffers Surprise Blow as New Bone Density Safety Concerns for MariTide Surface - BioSpace
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Aptus Capital Advisors LLC - MarketBeat
Amgen rebounds after denying bone safety concerns linked to obesity drug - MSN
Amgen stock gains as MariTide concerns addressed (AMGN:NASDAQ) - Seeking Alpha
Amgen Says No Link Between MariTide, Bone Density Loss - Marketscreener.com
Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug - Investing.com
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing - Yahoo Finance
Amgen dismisses bone density concerns related to its new weight-loss drug By Reuters - Investing.com
Amgen sees no bone safety concerns around experimental obesity drug - Marketscreener.com
0.24%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):